FDA instructs Amgen to pull Enbrel ads

02/22/2005 | NYTimes.com

The FDA ordered Amgen to pull its television ads for Enbrel, indicated for psoriasis, on grounds the advertisement did not disclose risks or mention the drug was indicated only for "chronic moderate to severe plaque psoriasis," and not milder forms. The agency also told the company its ad overstated Enbrel's effectiveness. An Amgen spokeswoman said the ad has been pulled and the company is reviewing the letter.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC